Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Fast Is The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Expected to Grow Between 2025 And 2029?
In recent times, the market size for chronic inflammatory demyelinating polyneuropathy (cidp) has seen robust growth. The market is projected to increase from $2.1 billion in 2024 to $2.27 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 8.1%. The growth registered during the historic period can be linked to factors such as a growing elderly population, enhancement in treatment alternatives, heightened awareness and early detection, progress in immunology and autoimmune studies, as well as a surge in autoimmune disease occurrences.
The market for chronic inflammatory demyelinating polyneuropathy (CIDP) is projected to witness notable growth in the coming years, expected to reach $3.09 billion by 2029, with a compound annual growth rate (CAGR) of 7.9%. The anticipated expansion during the forecast period is linked to an ageing global demographic, an increased emphasis on rare and autoimmune diseases, improved healthcare access, patient advocacy and awareness drives, and advancements in healthcare infrastructure. The forecast period is also expected to see significant trends including a rising incidence of chronic inflammatory demyelinating polyneuropathy, advancements in treatment alternatives, heightened research and development activities, the rise of biosimilar therapies, and the progress of personalized medicine approaches.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21144&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
The continued growth of the CIDP market is anticipated to be driven by the escalating healthcare spending. This surge in healthcare expenses stems from heightened investments in medical facilities, a burgeoning demand for cutting-edge therapies, comprehensive insurance policies, and persistent governmental initiatives to expand healthcare accessibility. Remarkably, higher healthcare costs facilitate access to advanced therapies resulting in early detection, better handling of CIDP, improved patient outcomes, and enhanced quality of life. For example, per the Office for National Statistics, a government agency in the UK, there was a notable increase of 5.6% in overall healthcare costs in nominal terms from the year 2022 to 2023. This increase was significantly higher compared to the mere 0.9% surge recorded in 2022. Therefore, the upswing in healthcare expenses is fueling the CIDP market’s growth.
Which Key Market Segments Comprise the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market and Drive Its Revenue Growth?
The chronic inflammatory demyelinating polyneuropathy (cidp)market covered in this report is segmented –
1) By Treatment: Intravenous Immunoglobulin; Corticosteroids; Plasmapheresis; Physiotherapy; Other Treatments
2) By Route Of Administration: Intravenous; Oral; Other Routes Of Administration
3) By Diagnosis: Electrodiagnostic Testing; Nerve Conduction; Electromyography (EMG); Spinal Fluid Analysis; Other Diagnosis
4) By Distribution Channel: Hospitals; Pharmacies; Online Pharmacies; Specialty Clinics
5) By End User: Hospitals; Research Institutions; Homecare Settings
Subsegments:
1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy; High-Dose IVIG Therapy
2) By Corticosteroids: Oral Corticosteroids; Intravenous Corticosteroids
3) By Plasmapheresis: Single-Exchange Plasmapheresis; Multiple-Exchange Plasmapheresis
4) By Physiotherapy: Muscle Strengthening Exercises; Balance And Coordination Therapy
5) By Other Treatments: Immunosuppressive Agents; Monoclonal Antibodies
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21144&type=smp
Which Areas Are Leading Regions in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Expansion Across the Globe?
North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2024. The regions covered in the chronic inflammatory demyelinating polyneuropathy (CIDP) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in theChronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Over the Coming Years?
Leading corporations in the chronic inflammatory demyelinating polyneuropathy (CIDP) industry are paying attention to advancements like intravenous immunoglobulin (IVIG) therapy. Their aim is to boost the effectiveness of treatment, increase patient results, and offer more precise and effective immune modulation for the control of CIDP. Intravenous immunoglobulin (IVIG) therapy is a process that incorporates the infusion of concentrated antibodies from healthy contributors to help adjust the immune system and decrease inflammation in autoimmune disorders. As an example, in January 2024, the Japan-based biopharmaceutical organization, Takeda Pharmaceutical Company Limited, gained FDA approval for GAMMAGARD LIQUID to be used as an intravenous immunoglobulin (IVIG) treatment for adults suffering from chronic inflammatory demyelinating polyneuropathy (CIDP). This endorsement permits its application as an induction treatment, commencing with an initial dosage followed by sustaining dosages to assist long-term disease control and improve neuromuscular operation.
View the full report here:
How Is the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Conceptually Defined?
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder that causes progressive weakness and impaired sensory function due to nerve inflammation and demyelination. It results from the immune system attacking the myelin sheath of peripheral nerves, leading to muscle weakness, numbness, and coordination issues.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21144
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model